Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Medicaid Use Of QALYs As Basis Of Drug Coverage Restrictions Would Be Barred By HHS Proposal

Executive Summary

Prohibition by Health and Human Services Department Office of Civil Rights would apply to use of such metrics in determining formulary access but not to use in ‘academic’ research.

You may also be interested in...



Medicare Unlikely To Embrace Cost Effectiveness In Early Price Negotiations – ICER’s Pearson

The government’s rush to stand up the negotiation program by the fall likely means an approach to cost effectiveness will be left out of at least the first cycle. But it could be incorporated over time.

QALY Control: House Bill Would Ban Cost-Effectiveness Tool In US Programs

No one seems eager to defend the QALY tool as a House Republican bill seeks to prohibit any federal agency from using Quality Adjusted Life Years as a formula to determine pricing.

IRA Innovation Debate Showcased At House Hearing On Rare Disease Legislation

Bills to narrow the Medicare price negotiation program’s reach generated extensive discussion at the hearing.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

PS149001

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel